Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Protagonist Therapeutics (PTGX) EBITDA Margin (2017 - 2025)

Protagonist Therapeutics' EBITDA Margin history spans 9 years, with the latest figure at 677.09% for Q4 2025.

  • For Q4 2025, EBITDA Margin fell 75392.0% year-over-year to 677.09%; the TTM value through Dec 2025 reached 343.63%, down 40260.0%, while the annual FY2025 figure was 343.63%, 40184.0% down from the prior year.
  • EBITDA Margin for Q4 2025 was 677.09% at Protagonist Therapeutics, up from 985.17% in the prior quarter.
  • Across five years, EBITDA Margin topped out at 1001.21% in Q4 2023 and bottomed at 4824.56% in Q2 2022.
  • The 5-year median for EBITDA Margin is 408.85% (2021), against an average of 662.33%.
  • The largest annual shift saw EBITDA Margin tumbled -1525634bps in 2021 before it skyrocketed 103367bps in 2023.
  • A 5-year view of EBITDA Margin shows it stood at 429.57% in 2021, then soared by 92bps to 32.46% in 2022, then surged by 3185bps to 1001.21% in 2023, then plummeted by -92bps to 76.84% in 2024, then plummeted by -981bps to 677.09% in 2025.
  • Per Business Quant, the three most recent readings for PTGX's EBITDA Margin are 677.09% (Q4 2025), 985.17% (Q3 2025), and 758.04% (Q2 2025).